{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460774030
| ImageFile = Dazoxiben.png
| ImageSize =
| ImageAlt =
| IUPACName =
| OtherNames =
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 09ZFC7974Q
| IUPHAR_ligand = 5175
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB03052
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 267473
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 78218-09-4
| PubChem = 53001
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 47885
| SMILES = O=C(O)c2ccc(OCCn1ccnc1)cc2
| InChI = 1/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
| InChIKey = XQGZSYKGWHUSDH-UHFFFAOYAY
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XQGZSYKGWHUSDH-UHFFFAOYSA-N
 }}
|Section2={{Chembox Properties
| C=12 | H=12 | N=2 | O=3 
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = 
 }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = 
 }}
}}

'''Dazoxiben''' is an orally active [[thromboxane synthase inhibitor]].<ref>{{Cite journal
 | doi = 10.1111/j.1365-2125.1983.tb02119.x
 | last1 = Belch | first1 = J. J.
 | last2 = Cormie | first2 = J.
 | last3 = Newman | first3 = P.
 | last4 = McLaren | first4 = M.
 | last5 = Barbenel | first5 = J.
 | last6 = Capell | first6 = H.
 | last7 = Leiberman | first7 = P.
 | last8 = Forbes | first8 = C. D.
 | last9 = Prentice | first9 = C. R.
 | title = Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial
 | journal = British Journal of Clinical Pharmacology
 | volume = 15 Suppl 1
 | issue = Suppl 1
 | pages = 113S–116S
 | year = 1983
 | pmid = 6337601
 | pmc = 1427695
}}</ref> It has shown a significant clinical improvement in patients with [[Raynaud's syndrome]].<ref>{{Cite journal
 | doi = 10.1111/j.1365-2125.1983.tb02119.x
 | last1 = Belch | first1 = J. J.
 | last2 = Cormie | first2 = J.
 | last3 = Newman | first3 = P.
 | last4 = McLaren | first4 = M.
 | last5 = Barbenel | first5 = J.
 | last6 = Capell | first6 = H.
 | last7 = Leiberman | first7 = P.
 | last8 = Forbes | first8 = C. D.
 | last9 = Prentice | first9 = C. R.
 | title = Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial
 | journal = British Journal of Clinical Pharmacology
 | volume = 15 Suppl 1
 | issue = Suppl 1
 | pages = 113S–116S
 | year = 1983
 | pmid = 6337601
 | pmc = 1427695
}}</ref>
==Synthesis==
[[File:Dazoxiben synthesis.svg|thumb|center|500px|Dazoxiben synthesis:<ref>{{Cite patent|DE|2950019}}</ref><ref>{{cite journal|doi=10.1007/BF02226528|title=Simplified synthesis of dazoxiben|journal=Pharmaceutical Chemistry Journal|volume=29|issue=2|pages=139|year=1995|last1=Kochergin|first1=P. M.|last2=Palei|first2=R. M.|last3=Balandina|first3=L. V.|last4=Kharitonova|first4=A. E.|last5=Kravchenko|first5=A. N.|last6=Persanova|first6=L. V.|last7=Govorukhina|first7=E. I.|last8=Frolova|first8=M. A.}}</ref><ref>{{cite journal|doi=10.1021/jm00142a005|pmid=7199088|title=Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives|journal=Journal of Medicinal Chemistry|volume=24|issue=10|pages=1139|year=1981|last1=Iizuka|first1=Kinji|last2=Akahane|first2=Kenji|last3=Momose|first3=Denichi|last4=Nakazawa|first4=Masayuki|last5=Tanouchi|first5=Tadao|last6=Kawamura|first6=Masanori|last7=Ohyama|first7=Isao|last8=Kajiwara|first8=Ikuo|last9=Iguchi|first9=Yohichi}}</ref><ref>{{cite journal|doi=10.1021/jm00148a009|pmid=3930740|title=Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles|journal=Journal of Medicinal Chemistry|volume=28|issue=10|pages=1427|year=1985|last1=Cross|first1=Peter E.|last2=Dickinson|first2=Roger P.|last3=Parry|first3=M. John|last4=Randall|first4=Michael J.}}</ref>]]
One convenient synthesis starts with the O-chloroethyl ether of p-hydroxybenzamide and proceeds bydisplacement with imidazole to give '''2'''. Hydrolysis of the amide function completes the synthesis of dazoxiben.

==References==
{{Reflist|2}}


{{Antithrombotics}}
{{Prostanoidergics}}

[[Category:Antithrombotic agents]]
[[Category:Imidazoles]]
[[Category:Benzoic acids]]


{{drug-stub}}